Terapia Adjuvante Guiada por ctDNA no Câncer Colorectal Ressecado: Revisão Sistemática e Meta-análise da Validade Prognóstica versus Utilidade Tratamento-Decisão
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of gastrointestinal cancer
- Publicado em
- 16 set 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Postoperative ctDNA-Guided Adjuvant Therapy in Resected Colorectal Cancer: A Systematic Review and Meta-analysis of Prognostic Validity Versus Treatment-Decision Utility
Zheng Han, Yan Zhang, Qingjie Tian, Hongcheng Zhu, Hongwei Wang, Changzai Li
Descritores MeSH
- Circulating Tumor DNA
- Neoplasm Recurrence, Local
- Biomarkers, Tumor
- Colorectal Neoplasms
- Chemotherapy, Adjuvant
- Humans
- Neoplasm, Residual
- Prognosis
Veja também
Estudos relacionados
- Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer - a review of current evidence and perspectives
- Prognostic Value of Circulating Tumor DNA for Recurrence Risk in Stage III Colorectal Cancer: A Systematic Review and Meta-Analysis
- Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual Disease and Recurrence Prediction in Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis
- Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis
- The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis
- Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial